Mahamaya Lifesciences Ltd.

BSE: 544611

SME

Sector: Chemicals

Industry Group: Fertilizers & Agrochemicals

Industry: Pesticides & Agrochemicals

185.35+2.3 (+1.28%)

9 Sep, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Mahamaya Lifesciences Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M PR	12M PR	12M AR	12M AR	12M AR
Total Revenue	113.51	89.91	137.08	161.57	264.15	328.87
Cost of Operating Revenue	105.49	76.50	119.73	140.59	228.57	277.08
Gross Profit	8.01	13.41	17.35	20.98	35.58	51.79
Gross Margin	7.1	14.9	12.7	13.0	13.5	15.7
Total Operating Expenses	109.11	84.81	128.86	149.60	241.49	297.60
Operating Profit	4.40	5.11	8.22	11.97	22.66	31.27
Operating Margin	3.9	5.7	6.0	7.4	8.6	9.5
Financing Income/(Expense) - Net	-0.50	-1.58	-3.36	-5.20	-5.67	-8.14
Profit before Taxes	3.90	3.72	5.10	7.43	17.25	23.88
Income Taxes	1.29	1.00	1.35	2.05	4.44	14.71
Profit after Tax	2.62	2.72	3.75	5.38	12.81	16.52
PAT Margin	2.3	3.0	2.7	3.3	4.9	5.0
EPS - Basic - ex Extraordinary Items	1.12	1.16	1.60	2.30	5.47	-
EPS - Diluted - ex Extraordinary Items	1.12	1.16	1.60	2.30	5.47	-
EBIT	4.40	5.11	8.22	11.97	22.66	31.27
EBITDA	4.93	6.06	9.49	13.38	24.47	33.51
EBITDA Margin	4.3	6.7	6.9	8.3	9.3	10.2

Balance Sheet

Abridged

Understanding Balance Sheet

Mahamaya Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	PR	PR	AR	AR	AR
Total Current Assets	23.87	33.32	54.00	87.32	156.65	266.45
Long-Term Investments	0.05	-	-	-	-	-
Property Plant & Equipment - Net	16.55	17.06	17.78	18.33	21.74	28.83
Total Non-Current Assets	20.25	22.39	23.88	24.78	31.62	43.83
Total Assets	44.12	55.71	77.88	112.10	188.27	310.28
Total Current Liabilities	20.12	30.02	47.66	78.00	131.55	183.13
Long Term Debt	10.72	9.68	10.30	8.55	6.16	3.57
Total Non-Current Liabilities	10.82	9.99	10.78	9.31	7.31	5.22
Total Liabilities	30.94	40.01	58.44	87.31	138.85	188.35
Total Shareholders' Equity	13.18	15.71	19.44	24.79	49.42	121.93
Total Equity	13.18	15.71	19.44	24.79	49.42	-
Total Liabilities & Equity	44.12	55.71	77.88	112.10	188.27	-

Cash Flow

Abridged

Understanding Cash Flow Statement

Mahamaya Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M PR	12M PR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	2.81	3.73	5.87	7.63	17.17	29.45
Working Capital - Increase/(Decrease)	6.89	-3.17	-7.58	-36.73	-27.04	-58.98
Net CF from Operating Activities	9.70	0.55	-1.71	-29.10	-9.87	-37.21
Capital Expenditures - Net	8.06	3.27	2.85	1.46	4.68	16.00
Net CF from Investing Activities	-7.68	-3.27	-2.87	-1.46	-4.72	-16.05
Stock - Issuance/(Retirement) - Net	-	-	-	-	13.79	5.64
Debt - LT & ST - Issuance/(Retirement) - Total	-2.66	3.00	5.21	30.25	3.41	32.62
Net Cash Flow from Financing Activities	-2.66	3.00	5.21	30.25	15.27	88.66
Free Cash Flow to Equity	-1.02	0.29	0.65	-0.31	-11.14	-20.58
Free Operating CF net dividend	1.64	-2.72	-4.60	-30.61	-14.91	-53.31
Free Operating CF	1.64	-2.72	-4.60	-30.61	-14.91	-53.31

Business Segment Analysis

FY End:

Mar 25

Mahamaya Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Agrochemical (100.0%)₹ 5.04 Cr

Revenue / Sales

Agrochemical (100.0%)₹ 264.15 Cr

Assets

Agrochemical (100.0%)₹ 188.27 Cr

Operating Income

Agrochemical (100.0%)₹ 22.66 Cr

Regional Segment Analysis

FY End:

Mar 25

Mahamaya Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (100.0%)₹ 264.15 Cr

Assets

India (100.0%)₹ 188.27 Cr

Historical Segment Analysis

Track how Mahamaya Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Agrochemical	8	3	3	2	5

Frequently Asked Questions

What is the revenue of Mahamaya Lifesciences Ltd.?

The latest trailing twelve month revenue of Mahamaya Lifesciences Ltd. is ₹ 328.87 Cr, reflecting a 1-year growth of 24.50% and a 3-year CAGR of 33.87%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Mahamaya Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Mahamaya Lifesciences Ltd. is ₹ 16.52 Cr, with a 3-year earnings CAGR of 73.23%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Mahamaya Lifesciences Ltd.?

The trailing twelve month EBITDA of Mahamaya Lifesciences Ltd. is approximately ₹ 31.27 Cr (based on an operating margin of 9.51%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Mahamaya Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Mahamaya Lifesciences Ltd. is 8.33. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Mahamaya Lifesciences Ltd.?

The debt-to-equity ratio of Mahamaya Lifesciences Ltd. stands at 0.74. The interest coverage ratio is 3.84x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Mahamaya Lifesciences Ltd.?

The estimated book value per share of Mahamaya Lifesciences Ltd. is 52.10 (derived from a P/B ratio of 3.56 and market price of ₹ 185.35), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Mahamaya Lifesciences Ltd.?

The trailing twelve month operating cash flow of Mahamaya Lifesciences Ltd. is ₹ -37.21 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Mahamaya Lifesciences Ltd. report consolidated or standalone financials?

Mahamaya Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.